Literature DB >> 3298449

The carboxylpropeptide of type I procollagen in skin fibrillogenesis.

R Fleischmajer, J S Perlish, B R Olsen.   

Abstract

Previous studies suggested that the aminopropeptide of type I procollagen may initiate fibril formation. The purpose of this investigation was to study the location of the carboxylpropeptide of type I procollagen during collagen fibrillogenesis. Chick embryonic and posthatching skin specimens were studied by immunofluorescence and immunoelectron microscopy and by immunoblotting with antibodies against the amino and carboxylpropeptide of type I procollagen. The carboxylpropeptide was demonstrated at the surface of collagen fibrils, 20-40 nm in diameter (10-day embryos) and in fibrils, 40-65 nm (21-day embryos). In addition, the carboxylpropeptide was found at the cell surface and free in the ground substance. The aminopropeptide was only seen in fibrils, 20-30 nm in diameter, as previously reported. Ratios of pN-collagen/pC-collagen increased from 16 days embryonic to 3 and 9 days postembryonic skins. This study suggests that both pN-collagen (aminopropeptide plus collagen) and pC-collagen (carboxylpropeptide plus collagen) participate in fibrillogenesis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3298449     DOI: 10.1111/1523-1747.ep12470949

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  3 in total

Review 1.  Collagen fibril formation.

Authors:  K E Kadler; D F Holmes; J A Trotter; J A Chapman
Journal:  Biochem J       Date:  1996-05-15       Impact factor: 3.857

2.  Developmental changes in the type I procollagen processing pathway in chick-embryo cornea.

Authors:  S J Mellor; G L Atkins; D J Hulmes
Journal:  Biochem J       Date:  1991-06-15       Impact factor: 3.857

Review 3.  Tendon Extracellular Matrix Assembly, Maintenance and Dysregulation Throughout Life.

Authors:  Seyed Mohammad Siadat; Danae E Zamboulis; Chavaunne T Thorpe; Jeffrey W Ruberti; Brianne K Connizzo
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.